Yahoo Finance’s Ines Ferre joins Zack Guzman to discuss the IPO class of 2020 and how the coronavirus could impact other companies looking to go public....
Data engineering and analytics company Cloudera Inc (NYSE: CLDR) surged about 19% on Tuesday following reports of the enterprise software company exploring strategic options.The Cloudera Analysts: Morgan Stanley analyst Sanjit Singh has an Overweight rating and $15 price target for Cloudera.Wells Fargo Securities analyst Philip Winslow has an Equal-Weight rating and $11 price target.Needham analyst Jack Andrews has a Hold rating.Sale Rumors Come Amid Recovery: The sale rumors come after Cloudera has seen three consecutive quarters of business stabilization following Hortonworks integration, Singh said. The company also has an updated product roadmap with the Cloudera Data Platform, or CDP.The analyst sees opportunities to sustain ARR growth, with the management committing to improving margins and cash flow.The fundamental story is undervalued, in light of the 18% drop in shares following last week's quarterly results that showed better-than-expected subscription revenue and operating margins, Singh said.The analyst noted that Robert Bearden, who was appointed...
Quill Intelligence LLC CEO and Director of Intelligence Danielle DiMartino Booth joins Yahoo Finance’s Zack Guzman to break down what investors should expect from the upcoming FOMC decision....
Sorrento Therapeutics’ (SRNE) competitors might be further down the line with their COVID-19 programs, but H.C. Wainwright analyst Ram Selvaraju highlights two separate routes the biotech could take to bring possible treatments and/or preventative therapies to market.Last week, Sorrento disclosed that in preclinical trials, the company’s monoclonal antibody (MaB), STI-4938, code named COVIDTRAP, inhibited SARS-CoV-2 viral infection in vitro.The data showed that STI-4938, an ACE2-Fc decoy protein, binds solidly to the SARS-CoV-2 virus spike protein, and is able to stop the virus from infecting the respiratory cells (specifically, in African green monkey kidney epithelial cells).Sorrento has another antibody in development, STI-1499 (COVI-SHIELD), which also recently demonstrated promising in vitro results as it was able to completely block the SARS-CoV-2 virus.While it is still early on for both antibodies, with the next stage involving preclinical animal studies, Selvaraju is encouraged by the additional positive results. “Together with Sorrento's previously announced preclinical neutralizing...
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]...
